Immunization with CD1d^hi-NIH3T3/Gal-ova confers protection against tumor development in mice. C57BL/6, CD4^−/−, or CD8^−/− mice were given 5 × 10⁵ NIH3T3-ova, NIH3T3/Gal-ova, CD1d^hi-NIH3T3-ova, or CD1d^hi-NIH3T3/Gal-ova intravenously. At 2 weeks later, the vaccinated mice were injected subcutaneously with 2 × 10⁵ of either EL4 or EG7 cells. Tumor size was measured at the indicated time points (n = 5-11 per group). Similar results were obtained in 2 independent experiments.